Join us Thursday 4/24 at 2pm Central Time, as we focus on the valuation range for Ford (F). Register here. HIDE

Catalyst Pharmaceutical (CPRX)

Add to Watchlists
Create an Alert
2.09 -0.03  -1.42% NASDAQ Apr 23, 10:38AM BATS Real time Currency in USD

Catalyst Pharmaceutical Research and Development Expense (Quarterly):

2.132M for June 30, 2013

View 4,000+ financial data types

View Full Chart

Catalyst Pharmaceutical Research and Development Expense (Quarterly) Chart

Export Data
Save Image

Catalyst Pharmaceutical Historical Research and Development Expense (Quarterly) Data

Export Data Date Range:
Viewing of   First  Previous First  Previous   Next  Last Next   Last
Data for this Date Range  
Dec. 31, 2013 2.068M
Sept. 30, 2013 2.804M
June 30, 2013 2.132M
March 31, 2013 1.092M
Dec. 31, 2012 0.7447M
Sept. 30, 2012 0.6548M
June 30, 2012 0.5327M
March 31, 2012 0.7273M
Dec. 31, 2011 0.9602M
Sept. 30, 2011 0.6141M
June 30, 2011 0.9056M
March 31, 2011 0.904M
Dec. 31, 2010 0.5692M
Sept. 30, 2010 0.5001M
June 30, 2010 0.7979M
March 31, 2010 0.4396M
Dec. 31, 2009 0.5476M
Sept. 30, 2009 0.851M
June 30, 2009 1.238M
March 31, 2009 Upgrade
Dec. 31, 2008 Upgrade
Sept. 30, 2008 Upgrade
June 30, 2008 Upgrade
March 31, 2008 Upgrade
Dec. 31, 2007 Upgrade
Sept. 30, 2007 Upgrade
June 30, 2007 Upgrade
March 31, 2007 Upgrade
Dec. 31, 2006 Upgrade
Sept. 30, 2006 Upgrade
June 30, 2006 Upgrade

There is no data for the selected date range.

An error occurred. Please try again by refreshing your browser or contact us with details of your problem.

About R&D Expense

R&D expenses are a line item from many companies' income statements.

R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
Learn More

Get data for

CPRX Research and Development Expense (Quarterly) Benchmarks

Biomarin Pharmaceutical 97.31M
Takeda Pharmaceutical 784.85M
Impax Laboratories 17.64M

CPRX Research and Development Expense (Quarterly) Range, Past 5 Years

Minimum 0.4396M Mar 2010
Maximum 2.804M Sep 2013
Average 1.004M

Already registered? Click here to sign in.

Access watchlists and custom data alerts.
Start your free account.

Get Started Now

Upgrade to {{}}. Start Your YCharts Membership. Start your {{}} Membership


{{ ? "Upgrade Now" : "Get Started Now"}}

Already a YCharts Member? Already a {{}} Member? Sign in here.